Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy
Observational studyHumans
- Design
- Observational study
- Subjects
- Muscle membranes from ALS and denervated patients tested in frog oocytes; a clinical cohort of 76 ALS patients, some treated with palmitoylethanolamide and some not
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Rundown of acetylcholine-evoked currents in transplanted muscle membranes; forced vital capacity over time in treated versus untreated ALS patients
What the authors reported
Palmitoylethanolamide reduced the rundown of acetylcholine currents in muscle membranes from ALS and denervated patients, acting on the adult epsilon-type receptor, and treated ALS patients had a slower decline in forced vital capacity than untreated patients.
Limits of this study
The laboratory part is careful; the clinical part is an unrandomised comparison of treated and untreated patients with no detail in the abstract on dose, duration or how treatment was chosen. Authors declare no conflicts. A related myasthenia gravis pilot is Onesti 2019.
Source
PubMed 26929355 · doi:10.1073/pnas.1600251113
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.